Recently, TMU Proton Center successfully treated a rare disease, atypical teratoid/rhabdoid tumor (AT/RT), and broke the age limitation of the disease’s traditional treatment.

The patient was only nine months old when admitted to Taipei Medical University Taipei Cancer Center (TMU Taipei Cancer Center) in August 2022. At that time, the tumor almost occupied the central part of the infant’s posterior cranial fossa, necessitating two surgeries for complete tumor removal. Fortunately, the surgeries were successful, and the patient recovered well.

In the past, craniospinal radiotherapy often led to unintended irradiation of a patient’s spine, negatively affecting their growth and hematopoietic system. The treatment carried a mere 40 percent survival rate, making it a challenging choice for patients. However, by adopting proton therapy, these risks can be effectively reduced or even eliminated.

TMU Healthcare System has been actively promoting precision medicine for children’s tumors and holistic healthcare. Through their close collaboration between Taipei Medical University Childhood Cancer team and TMU Proton Center, TMU Healthcare System stands at the forefront of delivering comprehensive cancer care solutions for children in the Taipei Metro Area.

Source: TMU Taipei Cancer Center and Office of Global Engagement